|
1.
|
Schömig M, Eisenhandt A and Ritz E: The
microinflammatory state of uremia. Blood Purif. 18:327–332.
2000.
|
|
2.
|
Kaysen GA: The microinflammatory state in
uremia: causes and potential consequences. J Am Soc Nephrol.
12:1549–1557. 2001.PubMed/NCBI
|
|
3.
|
Tsirpanlis G, Chatzipanagiotou S and
Nicolaou C: Microinflammation versus inflammation in chronic renal
faiure patients. Kidney Int. 66:2093–2098. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Memoli B, Postiglione L, Cianciaruso B, et
al: Role of different dialysis membranes in the release of
interleukin-6 soluble receptor in uremic patients. Kidney Int.
58:417–424. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Qureshi AR, Alvestrand A, Divino-Filho JC,
et al: Inflammation, malnutrition, and cardiac disease predictors
of mortality in hemodialysis patients. J Am Soc Nephrol. 13:28–36.
2002.PubMed/NCBI
|
|
6.
|
Schiffrin EL, Lipman ML and Mann JF:
Chronic kidney disease: effects on the cardiovascular system.
Circulation. 116:85–97. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Collins AJ: Cardiovascular mortality in
end-stage renal disease. Am J Med Sci. 325:163–167. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Silva LS, Oliveira RA, Silva GB, et al:
Cardiovascular disease in patients with end-stage renal disease on
hemodialysis in a developing country. Kidney Dis Transpl.
23:262–266. 2012.PubMed/NCBI
|
|
9.
|
Cozzolino M, Brancaccio D, Gallieni M and
Slatopolsky E: Pathogenesis of vascular calcification in chronic
kidney disease. Kidney Int. 68:429–436. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Levin A: Anemia and left ventricular
hypertrophy in chronic kidney disease populations: a review of the
current state of knowledge. Kidney Int Suppl. 80:35–38. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Memoli B, Minutolo R, Bisesti V, et al:
Changes of serum albumin and C-reactive protein are related to
changes of interleukin-6 release by peripheral blood mononuclear
cells in hemodialysis patients treated with different membranes. Am
J Kidney Dis. 39:266–273. 2002. View Article : Google Scholar
|
|
12.
|
Memoli B, Salerno S, Procino A, et al: A
translational approach to micro-inflammation in end-stage renal
disease: molecular effects of low levels of interleukin-6. Clin Sci
(Lond). 119:163–174. 2010. View Article : Google Scholar
|
|
13.
|
Fumeron C, Nguyen-Khoa T, Saltiel C, et
al: Effects of oral vitamin C supplementation on oxidative stress
and inflammation status in haemodialysis patients. Nephrol Dial
Transplant. 20:1874–1879. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Fakhrzadeh H, Poorebrahim R,
Shooshtarizadeh P, Raza M and Hosseini S: The effects of
consumption of omega3 fatty acid-enriched eggs on insulin and CRP.
Nutr Metab Cardiovasc Dis. 15:329–330. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Madsen T, Schmidt EB and Christensen JH:
The effect of n-3 fatty acids on C-reactive protein levels in
patients with chronic renal failure. J Ren Nutr. 17:258–263. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Taziki O, Lessan-Pezeshki M, Akha O and
Vasheghani F: The effect of low dose omega-3 on plasma lipids in
hemodialysis patients. Saudi J Kidney Dis Transpl. 18:571–576.
2007.PubMed/NCBI
|
|
17.
|
Micallef MA, Munro IA and Garg ML: An
inverse relationship between plasma n-3 fatty acids and C-reactive
protein in healthy individuals. Eur J Clin Nutr. 63:1154–1156.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Liepa GU and Basu H: C-reactive proteins
and chronic disease: what role does nutrition play? Nutr Clin
Pract. 18:227–233. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Magee P, Pearson S and Allen J: The
omega-3 fatty acid, eicosapentaenoic acid (EPA), prevents the
damaging effects of tumour necrosis factor (TNF)-alpha during
murine skeletal muscle cell differentiation. Lipids Health Dis.
7:242008. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Zoccali C, Mallamaci F and Tripepi G:
Novel cardiovascular risk factors in end-stage renal disease. J Am
Soc Nephrol. 15(Suppl 1): 77–80. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Jabs WJ, Theissing E, Nitschke M, et al:
Local generation of C-reactive protein in diseased coronary artery
venous bypass grafts and normal vascular tissue. Circulation.
108:1428–1431. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Devereux RB, Alonso DR, Lutas EM, et al:
Echocardiographic assessment of left ventricular
hypertrophy:comparison to necropsy findings. Am J Cardiol.
57:450–458. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Lee S, Kim IT, Park HB, et al:
High-sensitivity C-reactive protein can predict major adverse
cardiovascular events in Korean patients with type 2 diabetes. J
Korean Med Sci. 26:1322–1327. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Moubarak M, Jabbour H, Smayra V, et al:
Cardiorenal syndrome in hypertensive rats: microalbuminuria,
inflammation and ventricular hypertrophy. Physiol Res. 61:13–24.
2012.PubMed/NCBI
|
|
25.
|
Hohensinner PJ, Niessner A, Huber K,
Weyand CM and Wojta J: Inflammation and cardiac outcome. Curr Opin
Infect Dis. 24:259–264. 2011. View Article : Google Scholar
|
